XML 48 R37.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Revenues - Disaggregation of Revenues (Details) - USD ($) $ in Millions | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 30, 2018 | Sep. 30, 2017 | Sep. 30, 2018 | Sep. 30, 2017
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 5,596 | $ 6,512 | $ 16,332 | $ 20,158
U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 4,151 | 4,563 | 11,781 | 14,036
Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 975 | 1,271 | 3,116 | 4,088
Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 470 | 678 | 1,435 | 2,034
Atripla |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 258 | 439 | 921 | 1,366
Atripla | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 221 | 324 | 723 | 974
Atripla | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 29 | 79 | 119 | 259
Atripla | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 8 | 36 | 79 | 133
Biktarvy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 386 | 0 | 606 | 0
Biktarvy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 375 | 0 | 593 | 0
Biktarvy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 11 | 0 | 13 | 0
Biktarvy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Complera/Eviplera |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 139 | 237 | 528 | 744
Complera/Eviplera | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 61 | 91 | 210 | 315
Complera/Eviplera | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 67 | 133 | 279 | 385
Complera/Eviplera | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 11 | 13 | 39 | 44
Descovy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 406 | 316 | 1,170 | 853
Descovy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 310 | 241 | 895 | 682
Descovy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 81 | 65 | 234 | 149
Descovy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 15 | 10 | 41 | 22
Genvoya |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 1,176 | 988 | 3,418 | 2,614
Genvoya | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 921 | 810 | 2,678 | 2,189
Genvoya | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 203 | 146 | 596 | 358
Genvoya | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 52 | 32 | 144 | 67
Odefsey |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 423 | 296 | 1,150 | 781
Odefsey | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 323 | 255 | 905 | 688
Odefsey | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 95 | 37 | 230 | 87
Odefsey | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 5 | 4 | 15 | 6
Stribild |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 146 | 229 | 507 | 831
Stribild | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 111 | 181 | 388 | 632
Stribild | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 20 | 40 | 83 | 161
Stribild | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 15 | 8 | 36 | 38
Truvada |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 757 | 811 | 2,174 | 2,337
Truvada | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 665 | 604 | 1,821 | 1,635
Truvada | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 62 | 154 | 245 | 527
Truvada | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 30 | 53 | 108 | 175
Other HIV |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 14 | 15 | 46 | 41
Other HIV | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 10 | 13 | 30 | 34
Other HIV | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 2 | 2 | 6 | 5
Other HIV | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 2 | 0 | 10 | 2
Revenue share - Symtuza |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 22 | 0 | 42 | 0
Revenue share - Symtuza | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 8 | 0 | 8 | 0
Revenue share - Symtuza | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 14 | 0 | 34 | 0
Revenue share - Symtuza | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
AmBisome |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 102 | 92 | 312 | 276
AmBisome | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 9 | 9 | 40 | 26
AmBisome | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 59 | 51 | 170 | 153
AmBisome | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 34 | 32 | 102 | 97
Epclusa |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 477 | 882 | 1,513 | 2,945
Epclusa | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 225 | 543 | 733 | 2,142
Epclusa | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 136 | 263 | 502 | 649
Epclusa | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 116 | 76 | 278 | 154
Harvoni |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 311 | 973 | 990 | 3,726
Harvoni | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 185 | 718 | 649 | 2,628
Harvoni | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 38 | 110 | 116 | 583
Harvoni | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 88 | 145 | 225 | 515
Letairis |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 241 | 213 | 689 | 654
Letairis | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 241 | 213 | 689 | 654
Letairis | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Letairis | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Ranexa |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 178 | 164 | 581 | 517
Ranexa | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 178 | 164 | 581 | 517
Ranexa | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Ranexa | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Vemlidy |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 87 | 37 | 221 | 70
Vemlidy | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 66 | 34 | 172 | 66
Vemlidy | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 2 | 2 | 8 | 3
Vemlidy | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 19 | 1 | 41 | 1
Viread |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 70 | 274 | 249 | 834
Viread | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 17 | 137 | 40 | 395
Viread | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 10 | 55 | 72 | 202
Viread | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 43 | 82 | 137 | 237
Vosevi |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 103 | 123 | 319 | 123
Vosevi | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 78 | 117 | 250 | 117
Vosevi | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 21 | 5 | 57 | 5
Vosevi | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 4 | 1 | 12 | 1
Yescarta |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 75 | 0 | 183 | 0
Yescarta | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 75 | 0 | 183 | 0
Yescarta | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Yescarta | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 0 | 0 | 0 | 0
Zydelig |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 20 | 40 | 92 | 110
Zydelig | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 15 | 18 | 46 | 52
Zydelig | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 4 | 22 | 44 | 57
Zydelig | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 1 | 0 | 2 | 1
Other |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 64 | 273 | 285 | 1,003
Other | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 37 | 70 | 93 | 228
Other | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 19 | 33 | 75 | 279
Other | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 8 | 170 | 117 | 496
Product sales |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 5,455 | 6,402 | 15,996 | 19,825
Product sales | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 4,131 | 4,542 | 11,727 | 13,974
Product sales | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 873 | 1,197 | 2,883 | 3,862
Product sales | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Product revenue | 451 | 663 | 1,386 | 1,989
Royalty, contract and other revenues |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 141 | 110 | 336 | 333
Royalty, contract and other revenues | U.S. |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 20 | 21 | 54 | 62
Royalty, contract and other revenues | Europe |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | 102 | 74 | 233 | 226
Royalty, contract and other revenues | Other International |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Revenues | $ 19 | $ 15 | $ 49 | $ 45

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsAtriplaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsBiktarvyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsCompleraEvipleraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsDescovyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsGenvoyaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsOdefseyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsStribildMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsTruvadaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsEpclusaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsHarvoniMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsVemlidyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsVireadMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_AntiviralProductsVoseviMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |